Minocycline exerts acute inhibitory effects on cerebral cortex excitability in humans

Epilepsy Research

Volumn 107, Issue 3, 2013, Pages 302-305

  Lang, Nicolas ^a,c   Rothkegel, Holger ^a,c   Terney, Daniella ^b,c   Antal, Andrea ^c   Paulus, Walter ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b DANISH EPILEPSY CENTRE   (Denmark)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Epilepsy; Intracortical inhibition; Minocycline; Motor cortex; Silent period; Transcranial magnetic stimulation

Indexed keywords

MINOCYCLINE; PLACEBO;

ADULT; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG RESPONSE; EPILEPSY; EVOKED MUSCLE RESPONSE; HUMAN; HUMAN EXPERIMENT; IRRITATIVE COUGHING; MALE; MEAN CORTICAL SILENT PERIOD; NEGATIVE FEEDBACK; NERVE EXCITABILITY; NERVOUS SYSTEM PARAMETERS; NERVOUSNESS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TRANSCRANIAL MAGNETIC STIMULATION;

EPILEPSY; INTRACORTICAL INHIBITION; MINOCYCLINE; MOTOR CORTEX; SILENT PERIOD; TRANSCRANIAL MAGNETIC STIMULATION;

ADMINISTRATION, ORAL; ADULT; CEREBRAL CORTEX; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; MINOCYCLINE; MOTOR CORTEX; NEURAL INHIBITION; TRANSCRANIAL MAGNETIC STIMULATION; YOUNG ADULT;

EID: 84888430082     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.09.006     Document Type: Article

References (18)

1. Abraham J., Fox P.D., Condello C., Bartolini A., Koh S. Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures. Neurobiology of Disease 2012, 46:425-430.
2. Brundula V., Rewcastle N.B., Metz L.M., Bernard C.C., Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain: A Journal of Neurology 2002, 125:1297-1308.
3. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Medicine 2000, 6:797-801.
4. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:14669-14674.
5. Gonzalez J.C., Egea J., Del Carmen Godino M., Fernandez-Gomez F.J., Sanchez-Prieto J., Gandia L., Garcia A.G., Jordan J., Hernandez-Guijo J.M. Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca(2+) signalling in hippocampal neurons. European Journal of Neuroscience 2007, 26:2481-2495.
6. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., Tandan R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurology 2007, 6:1045-1053. Western ALS Study Group.
7. Goulden V., Glass D., Cunliffe W.J. Safety of long-term high-dose minocycline in the treatment of acne. British Journal of Dermatology 1996, 134:693-695.
8. Lang N., Sueske E., Hasan A., Paulus W., Tergau F. Pregabalin exerts oppositional effects on different inhibitory circuits in human motor cortex: a double-blind, placebo-controlled transcranial magnetic stimulation study. Epilepsia 2006, 47:813-819.
9. Lang N., Rothkegel H., Peckolt H., Deuschl G. Effects of lacosamide and carbamazepine on human motor cortex excitability: a double-blind, placebo-controlled transcranial magnetic stimulation study. Seizure 2013, pii: S1059-1311(13)00155-6. 10.1016/j.seizure.2013.05.010.
10. Leigh P.N., Meininger V., Bensimon G., Cudkowicz M., Robberecht W. Minocycline for patients with ALS. Lancet Neurology 2008, 7:119-120. (author reply 120-111).
11. Nowak M., Strzelczyk A., Reif P.S., Schorlemmer K., Bauer S., Norwood B.A., Oertel W.H., Rosenow F., Strik H., Hamer H.M. Minocycline as potent anticonvulsant in a patient with astrocytoma and drug resistant epilepsy. Seizure 2012, 21:227-228.
12. Paulus W., Classen J., Cohen L.G., Large C.H., Di Lazzaro V., Nitsche M., Pascual-Leone A., Rosenow F., Rothwell J.C., Ziemann U. State of the art: pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimulation 2008, 1:151-163.
13. Wang D.D., Englot D.J., Garcia P.A., Lawton M.T., Young W.L. Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo. Epilepsy & Behavior: E&B 2012, 24:314-318.
14. Wells J.E., Hurlbert R.J., Fehlings M.G., Yong V.W. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain: A Journal of Neurology 2003, 126:1628-1637.
15. Werhahn K.J., Kunesch E., Noachtar S., Benecke R., Classen J. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. Journal of Physiology 1999, 517(Pt 2):591-597.
16. Yong V.W., Wells J., Giuliani F., Casha S., Power C., Metz L.M. The promise of minocycline in neurology. Lancet Neurology 2004, 3:744-751.
17. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:13496-13500.
18. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.